Wall Street analysts expect that Valeritas Holdings Inc (NASDAQ:VLRX) will post $6.85 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Valeritas’ earnings. The highest sales estimate is $7.00 million and the lowest is $6.70 million. Valeritas reported sales of $5.07 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 35.1%. The company is expected to issue its next earnings results on Wednesday, November 14th.
On average, analysts expect that Valeritas will report full year sales of $26.90 million for the current financial year, with estimates ranging from $26.70 million to $27.10 million. For the next year, analysts anticipate that the business will report sales of $35.45 million, with estimates ranging from $35.00 million to $35.90 million. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Valeritas.
Valeritas (NASDAQ:VLRX) last announced its quarterly earnings data on Tuesday, August 7th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.11. The firm had revenue of $6.50 million during the quarter, compared to the consensus estimate of $6.30 million. Valeritas had a negative return on equity of 1,768.69% and a negative net margin of 205.12%.
VLRX has been the subject of several research analyst reports. Oppenheimer set a $4.00 price objective on Valeritas and gave the stock a “buy” rating in a research note on Tuesday, August 7th. initiated coverage on Valeritas in a research note on Thursday, July 5th. They set an “outperform” rating and a $3.50 price target for the company. ValuEngine raised Valeritas from a “hold” rating to a “buy” rating in a research note on Saturday, June 2nd. Finally, Citigroup initiated coverage on Valeritas in a research note on Thursday, July 5th. They set an “outperform” rating and a $3.50 price target for the company. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Valeritas currently has an average rating of “Buy” and an average target price of $3.67.
Shares of Valeritas stock opened at $1.33 on Friday. The stock has a market capitalization of $32.81 million, a P/E ratio of -0.16 and a beta of 4.14. The company has a debt-to-equity ratio of 13.66, a current ratio of 4.03 and a quick ratio of 3.42. Valeritas has a 1 year low of $0.78 and a 1 year high of $6.79.
Institutional investors and hedge funds have recently bought and sold shares of the company. Bainco International Investors acquired a new position in shares of Valeritas during the 2nd quarter valued at about $228,000. C WorldWide Group Holding A S increased its holdings in shares of Valeritas by 28.0% during the 2nd quarter. C WorldWide Group Holding A S now owns 316,194 shares of the company’s stock valued at $424,000 after acquiring an additional 69,216 shares during the last quarter. Finally, Essex Investment Management Co. LLC acquired a new position in shares of Valeritas during the 2nd quarter valued at about $448,000. 7.38% of the stock is owned by institutional investors.
Valeritas Holdings, Inc, a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States and China. It offers V-Go, a wearable insulin delivery device for basal-bolus therapy. The company also develops h-Patch, a controlled delivery technology platform; Mini-Ject technology for needle-free injection systems; and Micro-Trans technology for microneedle design, fabrication, and drug delivery.
Featured Article: Short Selling – Explanation For Shorting Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.